Robust Differentiation of NK Cells from MSLN.CAR-IL-15-Engineered Human iPSCs with Enhanced Antitumor Efficacy against Solid Tumors

By engineering LiPSC-GR1.1 with a mesothelin (MSLN)-targeting CAR and interleukin-15 (IL-15), researchers achieved robust differentiation of iPSCs into mature activated iNK cells with enhanced tumor killing efficacy, superior tumor homing, and vigorous proliferation.